Fig. 1: Schematic diagram of collateral sensitivity profiling (CSP). | Nature Communications

Fig. 1: Schematic diagram of collateral sensitivity profiling (CSP).

From: Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance

Fig. 1: Schematic diagram of collateral sensitivity profiling (CSP).The alternative text for this image may have been generated using AI.

Eighty antimicrobials covering a broad range of drug classes (control set for assay optimization) and an in-house library of 6195 natural product extract prefractions served as the primary source of chemical diversity for this study. Both the antimicrobial control set and the natural product library were systematically screened against wildtype E. coli (WT) and 29 drug-resistant strains (S1–S29) as either dilution series (antimicrobials) or at a single stock concentration (natural product prefractions); growth monitored via OD600 readings. Resulting bioactivity data for each antimicrobial and extract were normalized to wildtype values and used to construct a collateral sensitivity profile. CR cross resistance; drug-resistant strain(s) exhibiting decreased sensitivity to the drug/extract compared to wildtype (red). CS collateral sensitivity; drug-resistant strain(s) exhibiting increased sensitivity to the drug/extract compared to wildtype (blue). Diverse mechanisms of resistance across the target panel provides insight into the mechanism of collateral sensitivity: MDR multidrug resistance, RNA RNA synthesis, Cell Wall cell wall biosynthesis, Plasmid plasmid-borne multidrug resistance.

Back to article page